NCT03854903View on ClinicalTrials.gov

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

November 1, 2023

Study Completion Date

January 9, 2025

Conditions
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Interventions
DRUG

Palbociclib

Palbociclib is taken orally.

DRUG

Bosutinib

Bosutinib is taken orally.

DRUG

Fulvestrant

Fulvestrant is given as an intramuscular injection.

Trial Locations (1)

20007

Lombardi Comprehensive Cancer Center, Washington D.C.

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Georgetown University

OTHER

NCT03854903 - WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor | Biotech Hunter | Biotech Hunter